Neurocrine Biosciences Inc. (NBIX)

- Data Analyses Evaluate the Long-Term Benefit of INGREZZA® (valbenazine) 40 mg and Early Improvement to Treatment in Patients with Tardive Dyskinesia

SAN DIEGO, Sept. 30, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc.

- Phase III Data Analyses Evaluate the Long-Term Benefit of INGREZZA® (valbenazine) 40 mg and Early Response to Treatment in Patients with Tardive Dyskinesia

SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc.

SAN DIEGO, Aug. 28, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc.

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

- New Drug Application (NDA) is supported by data from pivotal Phase 3 studies of nearly 800 patients

INGREZZA® (valbenazine) Second Quarter Net Product Sales of $180.5 Million with Approximately 31,600 TRx

- FDA Accepts New Drug Application for Opicapone, a Once-Daily, Oral, Catechol-O-Methyltransferase (COMT) Inhibitor, as Adjunctive Therapy to Levodopa/Carbidopa

Conference Call and Webcast Scheduled for Monday, July 29

- INGREZZA Data from Long-Term Phase III Studies Support Sustained Clinical Benefit, Safety and Tolerability in Patients with Tardive Dyskinesia

Live Audio Webcast will be on June 11, 2019

Live Audio Webcast will be on June 6, 2019

- Nearly 30% of Patients with Possible Tardive Dyskinesia Reported Moderate-to-Extreme Problems Performing Their Usual Activities, Including Work, Housework and Leisure Activities

- RE-KINECT Analysis Provides Insight into the Impact of Possible Tardive Dyskinesia on Patient Health-Related Quality of Life

Live Audio Webcast will be on May 14, 2019

- Mental Health Advocacy Community Recognizes and 25 States Declare Tardive Dyskinesia Awareness Week as Part of Mental Health Month to Raise Prominence of Tardive Dyskinesia and Highlight the Impact on the Lives of Patients

- Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson's Disease

- More than 60% of Patients Treated with Once-Daily Opicapone 50 mg Experienced an Increase in Total ON Time of One Hour or Longer

- Long-Term Data from Two Phase III Trials Show INGREZZA Sustained Improvement in Tardive Dyskinesia Symptoms in Patients Taking Concomitant Medications for Psychiatric Disorders

INGREZZA® (valbenazine) First Quarter Net Product Sales of $136.4 Million with Approximately 24,200 TRx

Here are the top healthcare bets ticking all the boxes for analysts.

Stay active and selective: These are the five best stocks to invest in right now

Not every trade can be a winner, so let's lighten the load here.

Analysts weren't shy to defend the company after Tuesday's earnings.

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.